ARQT compared with PVLA: revenue, margins and what each company keeps, and the suppliers and customers both name

ARQTArcutis Biotherapeutics, Inc.

Mkt capRevenueRevenue

PVLAPalvella Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ARQTArcutis Biotherapeutics, Inc.

PVLAPalvella Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ARQT 5

AZNAstraZeneca ABsupplier

—Jiangsu Hengrui Medicineunlistedsupplier

—Hangzhou Zhongmei Huadong Pharmaceuticalunlistedcustomer

—Kowa Pharmaceuticals Americaunlistedcustomer

1 more · ARQT chain ›

Shared 0

No disclosed counterparties: PVLA.

Only PVLA 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

ARQTArcutis Biotherapeutics, Inc.

31.28▼−2.46%· post 31.27· delayed

Mkt cap$4.0BRevenue$130MQ2 FY26Revenue$376MFY25

PVLAPalvella Therapeutics, Inc.

146.83▲+0.47%· post 146.84· delayed

After hoursNov 2 '26delayed

Mkt cap—Revenue—Revenue—

Compare

After hoursNov 2 '26delayed

ARQTArcutis Biotherapeutics, Inc.

PVLAPalvella Therapeutics, Inc.

31.28▼−2.46%post 31.27delayed

Price

146.83▲+0.47%post 146.84delayed

$4.0B

Mkt cap

—

Q2 FY26$130M

Revenue

—

FY25$376M

Revenue

—

ARQT31.28▼−2.46%vsPVLA146.83▲+0.47%After hoursNov 2 '26delayed